Clinical Trials
3 trialsNCT04666038 2026-04-24
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT01897571 2024-03-26
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
Phase 1/2 Completed
NCT03483103 2023-12-20
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2 Completed